Abstract
Clinical outcomes of patients with chronic myeloid leukemia (CML) have drastically improved with tyrosine kinase inhibitors (TKIs). However, one of the main challenges is the management of intolerance experienced by patients with CML treated with TKI, resulting in poorer disease control. This targeted literature review examined the association of intolerance to TKIs in CML and clinical, economic and humanistic outcomes in a real-world setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
